ECM
ZYNE

Element Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Element Capital Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-27,551
Closed -$225K – 952
2018
Q3 		$225K Sell
27,551
-23,711
-46% -$182K ﹤0.01% 724
2018
Q2 		$499K Buy
+51,262
New +$525K 0.01% 372

Other funds holding ZYNE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Campbell Capital Management Miami, Florida $279M AUM 49.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Element Capital Management's ZYNE Position: Q4 2018 in Review

Element Capital Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2018, closing a stake of 27,551 shares — an estimated $225K sold.

Element Capital Management first reported a position in ZYNE in Q2 2018 and held it in 2 quarters. The position peaked at $499K in Q2 2018. 62 funds tracked by Wall St. Rank hold ZYNE as of Q4 2018.

  • Element Capital Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2018 after selling out during the quarter.
  • Element Capital Management sold 27,551 Zynerba Pharmaceuticals, Inc shares in Q4 2018, an estimated $225K.
  • Element Capital Management first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2018 and held it in 2 quarters.
  • Element Capital Management's Zynerba Pharmaceuticals, Inc position peaked at $499K in Q2 2018.
  • 62 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2018.

Based on Element Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.